A double-blind randomized trial of nicotine nasal spray as an aid in smoking cessation. 1997

T Blöndal, and M Franzon, and A Westin
Reykjavik Health Care Center, National University Hospital, Iceland.

The objective of the study was to evaluate the therapeutic efficacy of nicotine nasal solution (NNS) for smoking cessation from the stopping day up to 3 months. We also followed the participants for 2 yrs after ceasing smoking to assess what happens after stopping using NNS. In a placebo-controlled, double-blind, 2 yr prospective study, 157 smokers were given either NNS, one dose containing 1 mg of nicotine per 100 microL (n=79), or placebo (n=78). Treatment was continued for up to 1 yr. One day after quitting smoking, the average number of daily doses was 11 in the group assigned NNS and 14 in the group assigned the placebo, and after 6 weeks, 14 and 6 doses, respectively, among abstinent participants still using spray. After 3 months, 65% of the abstainers in the nicotine group were still using the NNS. The abstinence rates were 51, 39 and 29% after 6 weeks, 3 and 6 months, respectively, as compared to 24, 19 and 18% in the placebo group (p=0.0003; p=0.003; p=0.050). The proportion abstinent at the 1 yr (25 vs 17%) and 2 yr follow-ups (19 vs 14%) was higher among those assigned to the nicotine than to the placebo group, but not significantly so for the numbers used in the study. In conclusion, the use of nicotine nasal spray significantly increased the abstinence rate during the first 6 months following the quitting day.

UI MeSH Term Description Entries
D008297 Male Males
D009538 Nicotine Nicotine is highly toxic alkaloid. It is the prototypical agonist at nicotinic cholinergic receptors where it dramatically stimulates neurons and ultimately blocks synaptic transmission. Nicotine is also important medically because of its presence in tobacco smoke. Nicotine Bitartrate,Nicotine Tartrate
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000074606 Smoking Prevention Efforts directed at preventing SMOKING of TOBACCO and non-tobacco products. Anti-Smoking Campaign,Anti-Smoking Education,Anti Smoking Campaign,Anti Smoking Education,Anti-Smoking Campaigns,Anti-Smoking Educations,Campaign, Anti-Smoking,Campaigns, Anti-Smoking,Education, Anti-Smoking,Prevention, Smoking,Preventions, Smoking,Smoking Preventions
D000281 Administration, Intranasal Delivery of medications through the nasal mucosa. Drug Administration, Intranasal,Administration, Intranasal Drug,Administration, Nasal,Intranasal Administration,Intranasal Drug Administration,Administrations, Intranasal,Administrations, Intranasal Drug,Administrations, Nasal,Drug Administrations, Intranasal,Intranasal Administrations,Intranasal Drug Administrations,Nasal Administration,Nasal Administrations

Related Publications

T Blöndal, and M Franzon, and A Westin
December 1995, Addiction (Abingdon, England),
T Blöndal, and M Franzon, and A Westin
November 1994, Archives of internal medicine,
T Blöndal, and M Franzon, and A Westin
May 1996, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists,
T Blöndal, and M Franzon, and A Westin
January 1993, The Journal of the American Board of Family Practice,
T Blöndal, and M Franzon, and A Westin
September 2012, The European respiratory journal,
T Blöndal, and M Franzon, and A Westin
August 1992, Lancet (London, England),
T Blöndal, and M Franzon, and A Westin
January 1992, Ugeskrift for laeger,
T Blöndal, and M Franzon, and A Westin
March 1998, The Journal of the American Osteopathic Association,
T Blöndal, and M Franzon, and A Westin
March 1993, JAMA,
Copied contents to your clipboard!